Soda, a Brussels, Belgium-based provider of a data monitoring platform that streamlines how teams find the data worth fixing, raised €11.5M in Series A financing.
reMYND NV, a Leuven Belgium-based clinical stage company developing innovative treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction, extended its Series B financing round to €24m.
Endo Tools Therapeutics (ETT), a Gosselies, Belgium-based developer of advanced endoscopic medical devices for use by gastroenterologists, closed a Series D funding round of €8m ($9.5M).
Oqton, Inc., a Ghent, Belgium and San Francisco, USA – based software company specialising in AI-powered solutions for the manufacturing industry, raised over $40M in Series A financing.
Hootsuite, a global leader in social media management, acquired Sparkcentral, a Hasselt, Belgium and New York City-based provider of a social and digital customer care platform.
Urbantz, a Brussels, Belgium-based SaaS company aiming to increase efficiency and sustainability of last mile delivery operations, raised €6m in Series A funding.
Brikl, a Leuven, Belgium-based end-to-end 3D design and ecommerce software platform, secured $2.4m in growth funding.
Aphea.Bio, a Zwijnaarde, Belgium-based agtech startup, secured € 14m in Series B funding.
Edgard & Cooper, a Belgian manufacturer of quality dog and cat food, raised $22m in funding.
Oncomfort, a Wavre near Brussels, Belgium-based Digital SedationTM company, completed a €10m Series A funding.
Miracor Medical SA, an Awans, Belgium-based provider of innovative solutions for the treatment of severe cardiac diseases, closed a €24M Series E round of financing.
Indigo Diabetes, a Ghent, Belgium-based medical device company developing a novel invisible sensor for diabetes, raised €38M in Series B financing.
Boehringer Ingelheim, an Ingelheim, Germany-based market leader in animal health, acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company.
Skipr, a Brussels, Belgium-based B2B Mobility as a Service startup, raised €7m in funding.
eTheRNA immunotherapies, a Niel, Belgium-based clinical-stage company developing immunotherapies from its proprietary mRNA TriMix platform for the treatment of cancer and infectious diseases, raised Euro €34m in a Series B equity financing round.